Goldman Sachs Upgrades Biogen Idec (BIIB) to Buy, Adds To Buy List

January 27, 2009 7:25 AM EST Send to a Friend
Goldman Sachs upgrades Biogen Idec (Nasdaq: BIIB) from Neutral to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login